JPWO2019243822A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019243822A5 JPWO2019243822A5 JP2020571480A JP2020571480A JPWO2019243822A5 JP WO2019243822 A5 JPWO2019243822 A5 JP WO2019243822A5 JP 2020571480 A JP2020571480 A JP 2020571480A JP 2020571480 A JP2020571480 A JP 2020571480A JP WO2019243822 A5 JPWO2019243822 A5 JP WO2019243822A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- haloalkyl
- compound according
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000003545 alkoxy group Chemical group 0.000 claims 29
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 11
- 229910052801 chlorine Inorganic materials 0.000 claims 11
- 229910052731 fluorine Inorganic materials 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 229910052794 bromium Inorganic materials 0.000 claims 7
- 229910052740 iodine Inorganic materials 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 238000009833 condensation Methods 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 claims 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- UYWWLYCGNNCLKE-UHFFFAOYSA-N 2-pyridin-4-yl-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1=CC=NC=C1 UYWWLYCGNNCLKE-UHFFFAOYSA-N 0.000 claims 1
- GSSXLFACIJSBOM-UHFFFAOYSA-N 2h-pyran-2-ol Chemical compound OC1OC=CC=C1 GSSXLFACIJSBOM-UHFFFAOYSA-N 0.000 claims 1
- WXLPKTIAUMCNDX-UHFFFAOYSA-N 2h-pyran-3-ol Chemical compound OC1=CC=COC1 WXLPKTIAUMCNDX-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1810071.9A GB201810071D0 (en) | 2018-06-19 | 2018-06-19 | Compounds |
| GB1810071.9 | 2018-06-19 | ||
| PCT/GB2019/051728 WO2019243822A1 (en) | 2018-06-19 | 2019-06-19 | 1,2,4-triazole derivatives as tankyrase inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021533085A JP2021533085A (ja) | 2021-12-02 |
| JP2021533085A5 JP2021533085A5 (https=) | 2022-06-24 |
| JPWO2019243822A5 true JPWO2019243822A5 (https=) | 2022-06-24 |
| JP7445266B2 JP7445266B2 (ja) | 2024-03-07 |
Family
ID=63042576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571480A Active JP7445266B2 (ja) | 2018-06-19 | 2019-06-19 | タンキラーゼ阻害剤としての１，２，４－トリアゾール誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11926614B2 (https=) |
| EP (1) | EP3810597B1 (https=) |
| JP (1) | JP7445266B2 (https=) |
| KR (1) | KR20210024019A (https=) |
| CN (1) | CN112469714B (https=) |
| CA (1) | CA3103879A1 (https=) |
| ES (1) | ES3056990T3 (https=) |
| GB (1) | GB201810071D0 (https=) |
| WO (1) | WO2019243822A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202010359D0 (en) * | 2020-07-06 | 2020-08-19 | Univ Oslo Hf | Compounds |
| EP4247811A1 (en) * | 2020-11-19 | 2023-09-27 | F. Hoffmann-La Roche AG | Bicyclo[1.1.1]pentane compounds for the treatment and prophylaxis of hepatitis b virus infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4302051A1 (de) * | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| WO2010139966A1 (en) | 2009-06-05 | 2010-12-09 | Oslo University Hospital Hf | Azole derivatives as wtn pathway inhibitors |
| JP2013544874A (ja) | 2010-12-08 | 2013-12-19 | オスロ ユニヴァーシティー ホスピタル エイチエフ | Ｗｎｔシグナル伝達経路阻害薬としてのトリアゾール誘導体 |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| US10392378B2 (en) | 2014-12-23 | 2019-08-27 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| WO2018118868A1 (en) | 2016-12-19 | 2018-06-28 | Oslo University Hospital Hf | Triazole derivatives as tankyrase inhibitors |
-
2018
- 2018-06-19 GB GBGB1810071.9A patent/GB201810071D0/en not_active Ceased
-
2019
- 2019-06-19 WO PCT/GB2019/051728 patent/WO2019243822A1/en not_active Ceased
- 2019-06-19 ES ES19734147T patent/ES3056990T3/es active Active
- 2019-06-19 JP JP2020571480A patent/JP7445266B2/ja active Active
- 2019-06-19 CA CA3103879A patent/CA3103879A1/en active Pending
- 2019-06-19 US US17/253,668 patent/US11926614B2/en active Active
- 2019-06-19 CN CN201980048153.4A patent/CN112469714B/zh active Active
- 2019-06-19 EP EP19734147.2A patent/EP3810597B1/en active Active
- 2019-06-19 KR KR1020217001542A patent/KR20210024019A/ko not_active Ceased